Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04268498
Title A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

multiple myeloma

Therapies

Carfilzomib + Dexamethasone + Lenalidomide

Bortezomib + Dexamethasone + Lenalidomide

Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Miami Recruiting Miami Florida 33136 United States Details
Moffitt Cancer Center Not yet recruiting Tampa Florida 33612-9497 United States Details
Rush University Medical Center Not yet recruiting Chicago Illinois 606012 United States Details
Roswell Park Comprehensive Cancer Center Not yet recruiting Buffalo New York 14203 United States Details
Memorial Sloan Kettering Cancer Center Recruiting New York New York 10065 United States Details
Stony Brook University Not yet recruiting Stony Brook New York 11794 United States Details
MD Anderson Cancer Center Not yet recruiting Houston Texas 77030 United States Details
Huntsman Cancer Institue Not yet recruiting Salt Lake City Utah 84113 United States Details
Skåne University Hospital Not yet recruiting Malmö 9, 214 Sweden Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field